Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents
Clinical trial NCT06816771 · RECRUITING
Trial details
- NCT number
- NCT06816771
- Sponsor
- Shandong Cancer Hospital and Institute
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-01
- Primary completion
- 2025-12-31
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.